Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2024-04-25 Transaction in Own Shar…
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
关于部分限制性股票定向回购股份方案公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company regarding a specific share repurchase plan related to restricted stock under an equity incentive plan. It details the board and supervisory meetings approving the repurchase, the basis for the repurchase, the number of shares to be repurchased and cancelled, the price, and the impact on share capital and ownership structure. It also includes legal opinions and compliance with company law regarding creditor protection. The document is not a full financial report, earnings release, or management discussion, but a specific announcement about a share repurchase related to equity incentives. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is under 5,000 characters, but it contains detailed information about the repurchase plan itself, not just a notice of report publication. Therefore, the correct classification is POS with high confidence.
2024-04-25 Chinese
第三届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Huizhou Jin Hao Medical Technology Co., Ltd. It details the convening and attendance of the third meeting of the third Supervisory Board, and the approval of several proposals including the 2024 Q1 report, stock incentive plans, and stock repurchase plans. The document references other announcements published on the Beijing Stock Exchange disclosure platform but does not contain the actual financial report or detailed data itself. It is a formal meeting resolution announcement rather than the report or financial data. This fits the category of Board/Management Information (MANG), as it concerns internal governance meeting decisions and approvals by the supervisory board.
2024-04-25 Chinese
第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the third board of directors of Huizhou Jin Hao Medical Technology Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other announcements and reports published elsewhere. The document does not contain full financial statements or detailed financial data itself but rather reports on board decisions, including approval of a quarterly report and other corporate governance matters. It is not a full annual or quarterly report, nor is it a call transcript or earnings release. The content fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2024-04-25 Chinese
关于召开2024年第一次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. It does not contain financial statements, audit results, or detailed financial data. It is not a report but an announcement about a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself rather than solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. The document length is short (2572 characters), and it is primarily an announcement of a meeting, not the meeting results or proxy materials. Hence, the best fit is Regulatory Filings (RNS).
2024-04-25 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 First Quarter Report" of 惠州市锦好医疗科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow data, and management's discussion of financial performance for the period ending March 31, 2024. The report explicitly states it is unaudited and covers the first quarter of 2024, which aligns with the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese
关于调整2022年股权激励计划限制性股票价格和数量的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Huizhou Jin Hao Medical Technology Co., Ltd. regarding adjustments to the 2022 equity incentive plan, specifically the restricted stock price and quantity. It includes references to multiple board and supervisory meetings, legal opinions, and independent director opinions related to the equity incentive plan. The document discusses the adjustment methods for stock quantities and prices due to capital reserve transfers, dividends, and other corporate actions. It also mentions the impact on financial status and compliance with relevant laws and regulations. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is a regulatory announcement about changes in the equity incentive plan, which is a corporate governance and management-related disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2024-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.